Levation Pharma Company Profile
Levation Pharma, a Tel Aviv-based private biotech company founded in 2017 with two employees and venture capital backing, develops a topical oxymetazoline aqueous gel for treating droopy upper eyelids (ptosis) to improve visual fields and eye appearance, holds 20 patent documents including 13 granted patents related to alpha-adrenergic compositions, and has received multiple rounds of venture funding including a $2.6M early-stage VC round in 2018 and a later-stage VC deal in 2022.
Overview
Levation Pharma is a private biotechnology company founded in 2017 and headquartered in Tel Aviv, Israel. The company has 2 employees and is venture capital-backed.
Description
Levation Pharma develops a topical oxymetazoline product designed for cosmetic eye lifts. The company offers a drying aqueous gel composed of a transdermal formulation of oxymetazoline for the treatment of droopy upper eyelids (ptosis or blepharoptosis). This enables patients to raise the upper lid and improve both their upper visual fields and the appearance of the eye.
Contact Information
- Website: www.levationpharma.com
- Corporate Office: 45 Rothschild Boulevard, Tel Aviv 6578403, Israel
Industry
- Primary Industry: Biotechnology
- Other Industries: Pharmaceuticals
- Verticals: LOHAS & Wellness, HealthTech, Life Sciences
Valuation & Funding
- Latest Deal Type: Later Stage VC (28-Jun-2022)
- Previous Funding:
- Early Stage VC (12-Feb-2018): $2.6M (Completed)
- Early Stage VC (01-Jan-2021): $6M (Cancelled)
- Secondary Transaction - Private (01-May-2022): Completed
Cap Table
- Preferred A shares authorized (details not disclosed)
Patent Portfolio
- Total Documents (Applications and Grants): 20
- Total Patent Families: Not specified
- Granted: 13
- Pending: 6
- Expiring in next 12 months: Not specified
Recent Patent Activity
- WO-2025171327-A1: Methods for producing dermatological gel compositions (Pending, 09-Feb-2024)
- JP-2022058765-A: Composition and use of alpha adrenaline agonists (Pending, 26-Jan-2016)
- CA-3012660-A1: Composition of alpha-adrenergic agents for the treatment of ptosis (Active, 26-Jan-2016)
- AU-2017211793-A1: Compositions and uses of alpha-adrenergic agents (Active, 26-Jan-2016)
- AU-2017211793-B2: Compositions and uses of alpha-adrenergic agents (Active, 26-Jan-2016, A61K45/00)
Investors
- Peregrine Ventures (Venture Capital, Minority holding)
- Pontifax Venture Capital (Venture Capital, Minority holding)
Competitors
- RVL Pharmaceuticals (Formerly PE-Backed, Bridgewater, NJ)
Frequently Asked Questions
When was Levation Pharma founded?
Levation Pharma was founded in 2017.
Where is Levation Pharma headquartered?
Levation Pharma is headquartered in Tel Aviv, Israel.
What is the size of Levation Pharma?
Levation Pharma has 2 total employees.
What industry is Levation Pharma in?
Levation Pharma’s primary industry is Biotechnology.
Is Levation Pharma a private or public company?
Levation Pharma is a private company.
How much funding has Levation Pharma raised over time?
Levation Pharma has raised $2.6M.
Who are Levation Pharma’s investors?
Peregrine Ventures and Pontifax Venture Capital have invested in Levation Pharma.
Who are Levation Pharma’s competitors?
RVL Pharmaceuticals is a competitor of Levation Pharma.